-- Merck KGaG Doesn’t Expect Erbitux Lung Tumor Approval, FTD Says
-- B y   K a r i n   M a t u s s e k
-- 2012-02-14T06:54:43Z
-- http://www.bloomberg.com/news/2012-02-14/merck-kgag-doesn-t-expect-erbitux-lung-tumor-approval-ftd-says.html
-  Merck KGaA (MRK)  says that its Erbitux
drug has less than a 50 percent chance of being approved for
lung tumor treatment, Financial Times Deutschland reported,
citing a briefing for  JPMorgan Chase & Co . analysts.  Erbitux is the company’s second biggest seller after its
Rebif multiple-sclerosis treatment, according to the newspaper.  To contact the reporters on this story:
Karin Matussek in Berlin at 
 kmatussek@bloomberg.net   To contact the editor responsible for this story:
Anthony Aarons at 
 aaarons@Bloomberg.net . 